Kiadis Pharma to announce annual results for the year ended December 31, 2019 on Thursday April 30, 2020
28 Abril 2020 - 3:30PM
Kiadis Pharma to announce annual results for the year ended
December 31, 2019 on Thursday April 30, 2020
Kiadis Pharma to announce annual
results for the year ended December 31, 2019 on Thursday April 30,
2020
Amsterdam, The Netherlands, April 28,
2020 – Kiadis Pharma N.V. ( “Kiadis”, “Kiadis Pharma” or the
“Company”) (Euronext Amsterdam and Brussels: KDS), a
clinical-stage biopharmaceutical company, will be announcing its
Annual Results for the year ended December 31, 2019 at 17:30 CET on
Thursday, April 30, 2020. The Kiadis management will also be
hosting an analyst and investor conference call at 18:00 CET /
12:00pm EDT on Thursday, April 30, 2020.
Conference Call and PresentationTo participate
in the conference call, please call one of the following numbers
ten minutes prior to commencement of the call:Standard
International: +44 (0) 2071 928338Netherlands, Amsterdam: +31 (0)
207956614UK, London: +44 (0) 8444819752US, New York:
+16467413167US, toll free: 18778709135
Event Plus Passcode: 4968027
A live audio webcast of the call can be accessed from the Events
and Presentations section of the Company’s website,
https://ir.kiadis.com/events-and-presentations or at
https://edge.media-server.com/mmc/p/6ctgdx37.
For more information, please
contact:
Kiadis Pharma:
Maryann Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617)
710-7305 m.cimino@kiadis.com |
Optimum Strategic
Communications: Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144 David Brilleslijper (Amsterdam) Tel: +31 610
942 514 kiadis@optimumcomms.com |
About Kiadis PharmaFounded in
1997, Kiadis Pharma is building a fully integrated
biopharmaceutical company committed to developing innovative
therapies for patients with life-threatening diseases. With
headquarters in Amsterdam, the Netherlands, and offices and
activities across the United States, Kiadis Pharma is reimagining
medicine by leveraging the natural strengths of humanity and our
collective immune system to source the best cells for life. Kiadis
Pharma is listed on the regulated market of Euronext Amsterdam and
Euronext Brussels since July 2, 2015, under the symbol KDS. Learn
more at kiadis.com.
Forward Looking
StatementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma’s
or, as appropriate, Kiadis Pharma’s officers’ current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of known and unknown
risks, uncertainties and assumptions that could cause actual
results, performance, achievements or events to differ materially
from those expressed, anticipated or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance, achievements or
results to differ significantly from any anticipated or implied
development. Forward-looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.